Novel Aldo-Keto Reductase 1C3 Inhibitor Affects Androgen Metabolism but Not Ovarian Function in Healthy Women: A Phase 1 Study

    June 2023 in “ European Journal of Endocrinology ”
    Isabella Gashaw, Stefanie Reif, Herbert Wiesinger, Andreas Kaiser, Frank S. Zollmann, Christian Scheerans, Joachim Grevel, Paolo Piraino, Henrik Seidel, Michaele Peters, Antje Rottmann, Beate Rohde, Wiebke Arlt, Jan Hilpert
    TLDR The inhibitor affects androgen metabolism but not ovarian function.
    A phase 1 study investigated the effects of a novel aldo-keto reductase 1C3 (AKR1C3) inhibitor on androgen metabolism and ovarian function in healthy women. The study found that serum androsterone is a strong biomarker for the response to AKR1C3 inhibitor treatment. Importantly, the administration of the inhibitor for 4 weeks did not impact ovarian function, suggesting that the treatment selectively affects androgen metabolism without altering ovarian health.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results